Cullinan Therapeutics公司宣布,其研发的新型Flt3xCD3 T细胞衔接器CLN-049,已获得美国食品药品监督管理局(FDA)授予的孤儿药资格认定,适应症为复发或难治性急性髓系白血病(AML)。
Cullinan Therapeutics公司宣布,其研发的新型Flt3xCD3 T细胞衔接器CLN-049,已获得美国食品药品监督管理局(FDA)授予的孤儿药资格认定,适应症为复发或难治性急性髓系白血病(AML)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.